Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4RMC9
|
|||
| Drug Name |
Rilvegostomig
|
|||
| Synonyms |
AZD2936
Click to Show/Hide
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1/2 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | . | [1] |
| V-set and immunoglobulin domain-containing protein 9 (TIGIT) | Target Info | . | [1] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.